Acute liver failure is a severe clinical syndrome accompanied with excessive inflammatory response. Our previous study demonstrated that SKLB023, a novel thiazolidinedione derivative, showed potent antiinflammatory activity in rheumatoid arthritis. The purpose of the present study is to evaluate the protective effect of SKLB023 on lipopolysaccharide (LPS)/D-GalN-induced liver failure and to explore the underlying molecular mechanisms. Our results showed that SKLB023 significantly improved mortality and liver injury as indicated by reduced serum levels of aminotransferases and alleviated pathological damage. Additionally, SKLB023 decreased the percentage of activated T cells and macrophages as well as the serum levels of cytokines in vivo. Furthermore, SKLB023 decreased levels of TNF-a and IL-6 secreted from liver macrophages (Kupffer cells) stimulated by LPS in vitro. Our results indicated that the protective effects of SKLB023 were associated with its significant impact on the inflammatory cytokines, which were produced by both T cells and macrophages.
Introduction
Acute liver failure, induced by bacteria, viral hepatitis, alcohol and other hepatotoxic drugs, is a severe clinical syndrome which is characterized by hepatic encephalopathy, severe coagulopathy, jaundice, and hydroperitoneum.
1,2 Apart from liver transplantation, there are still lack of available therapies, with a high mortality (80-90%) observed in patients. [3] [4] [5] Immune dysregulation plays a central role in the pathogenesis of ALF, in which massive leucocyte inltration of the injured liver is contrasted by a depletion and dysfunction of immune cells in circulation. 6, 7 Additionally, autoimmune hepatitis in humans has been demonstrated to be initiated by activation of T cells and macrophages. [8] [9] [10] These cells either directly attack liver parenchymal cells or induce tissue damage by the release of several proinammatory cytokines, such as TNF-a and IFN-g.
Cytokines are categorized into Th1-and Th2-type cytokines, which are secreted from different helper T cell populations.
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Some studies suggested that Th1 cytokines behave as proinammatory mediators involved in the pathogenesis of the liver toxicity, which has been demonstrated in immunemediated liver injury induced by LPS and concanavalin A.
12,13
Therefore, decreased of Th1-type cytokines and increased of Th2-type cytokines might be benet to the treatment of ALF.
LPS/D-GalN-induced liver injury in mice is usually considered an experimental model for clinical endotoxic shock or septic shock.
14 In this model, LPS exerts its effects by stimulating inammatory cells and hepatic kupffer cells to produce various pro-inammatory cytokines, including interferongamma (IFN-g), tumor necrosis factor-alpha (TNF-a), and interleukin-6 (IL-6). 15, 16 Injection of mice with GalN followed by LPS administration induces acute liver injury within 8 h aer application. 17, 18 Some research papers indicated that depletion of monocytes/macrophages to be protective, reducing liver injury.
19,20
In our previous work, (Z)-N-(3-chlorophenyl)-2-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)acetamide (SKLB023, Fig. S1 †) was synthesized and evaluated for its potently antiinammatory effect through inhibiting the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2).
21
Furthermore, SKLB023 attenuated joint inammation and cartilage destruction in arthritis models via suppression of NF-kB activation in macrophage. 22 However, whether SKLB023 showed anti-inammatory effect on LPS/D-GalN induced acute liver failure remains unknown until now. In the present study, we rst investigated the protection of SKLB023 against LPS/D-GalNinduced acute liver injury in vivo, and then examined the inhibitory effect of SKLB023 on the activation of T cells and macrophages. Finally, we tested whether SKLB023 inhibited the production of proinammatory cytokines secreted by T cells and macrophages. Our results demonstrated that SKLB023 protected mice from severe liver injury likely through inhibiting the production of cytokines and the activation of T cells and macrophages.
Results

Effect of SKLB023 on survival rate aer LPS/GalN administration
To investigate the effects of SKLB023 on LPS/GalN-induced lethality, the survival rate was observed within 24 h aer LPS/ GalN treatment (Fig. 1) . The results showed that the survival rate of the LPS/GalN treated group was 16%. 25 and 50 mg kg À1 SKLB023 signicantly increased the survival rate (66% and 83%), which higher than that of 100 mg kg À1 N-acetyl-L-cysteine
is commonly used in the treatment of ALF as a thiol antioxidant. 23 In the present study, NAC was employed as positive control.
Effect of SKLB023 on LPS/D-GalN-induced acute hepatic injury
LPS/D-GalN-induced acute hepatic injury mice model was performed and SKLB023 was orally administrated. Histological examination of liver tissue sections showed no pathological changes in normal mice ( Fig. 2A) . However, congestion, hepatocyte necrosis, destruction of hepatic architecture, and massive immigration of inammatory cells into the sinusoids were observed at 8 h aer LPS/D-GalN administration (Fig. 2B ). The treatment with 25 and 50 mg kg À1 of SKLB023 only showed patchy necrosis of hepatocytes and a slight immigration of inammatory cells (Fig. 2C and D) . In addition, the histological scores of mice signicantly decreased by 25 mg kg À1 (**P < 0.01) and 50 mg kg À1 (***P < 0.001) of SKLB023, which compared with the LPS injected mice (Fig. 2E) . Furthermore, Mice treated with SKLB023 showed a signicant reduction of plasma AST, ALT and ALB ( Fig. 2F-H 
Effect of SKLB023 on the levels of serum inammatory cytokines in LPS/D-GalN stimulated mice
The levels of serum TNF-a and IL-6 were determined by ELISA, and the results were showed in Fig. 4 . LPS/D-GalN administration signicantly increased the levels of TNF-a and IL-6 in the serum of mice, however, SKLB023 signicantly inhibited the production of TNF-a in the serum (Fig. 4A ). SKLB023 also suppressed the expression of IL-6 ( Fig. 4B ), although the difference was not statistically signicant.
Effect of SKLB023 on proinammatory cytokines production in T cells in vitro
The effect of SKLB023 on the activation of T cells was investigated by ow cytometry analysis. As illustrated in ; 2.7, 3.9, and 3.5% for CD8 + at 5, 10, and 20 mM of SKLB023, respectively).
The production of IFN-g and IL-4 in T cells and culture supernatants of the spleen cells isolated from mice were measured by FACS (Fig. 5) . The expression levels of intracellular cytokines IFN-g and IL-4, produced by CD4 + or CD8 + T cells were determined by Flow cytometry (Fig. 5) . The production of IFN-g was raised aer stimulated by ConA in both CD4 + T cells (Fig. 5A , from 0.2% to 1.0%) and CD8 + T cells (Fig. 5B, from 6.8% to 22.4%). However, SKLB023 suppressed the production 
Effect of SKLB023 on proinammatory cytokines production in liver macrophages
Our previous studies indicated that SKLB023 shown potential anti-inammatory activity in RAW264.7 cells. 22 In present investigation, we analyzed the effect of SKLB023 on the cytokines production of liver macrophages (Kupffer cells) stimulated by LPS in vitro. SKLB023 signicantly decreased the cytokines secreted by these macrophages. The expression levels of TNF-a and IL-6 were decreased by SKLB023 in a dosedependent manner at 48 and 72 hours (Fig. 6) . The level of TNF-a increased to 1079.2 pg ml À1 at 48 h and 1232.1 pg ml À1 at 72 h aer LPS stimulated, however, different concentrations of SKLB023 signicantly decreased the level of TNF-a to 729.5, 633.1 (*P < 0.05), and 370.2 (**P < 0.01) pg ml À1 at 48 h (Fig. 6A) , and 874.6, 649.7 (**P < 0.01), and 455.3 (***P < 0.001) pg ml À1 at 72 h (Fig. 6B) . Additionally, SKLB023 decreased the level of IL-6 at 5, 10, and 20 mM within 48 h (Fig. 6C ) and 72 h (Fig. 6D ).
Discussion
LPS/D-GalN-induced liver injury is a well-established experimental model that closely resembles human fulminant hepatitis in both morphological and functional features. When sensitized by the specic hepatotoxic D-GalN, a low dose of LPS could induce severe hepatic damage. 24, 25 In the present study, a novel synthetic small-molecule compound (SKLB023) ameliorated liver damage in LPS/D-GalN-induced liver injury model with a reduction in serum TNF-a and IL-6. SKLB023 signicantly elevated the survival rate of LPS/D-GalN-induced ALF, and also decreased the activation T cells and macrophages in the liver of mice stimulated by LPS. Furthermore, SKLB023 signicantly suppressed the production of inam-matory cytokines in both T cells and macrophages in vitro.
In LPS/D-GalN-induced liver injury model, we found the number of CD3 positive T cells and the percentage of CD68, CD11b and F4/80 positive cells were decreased by SKLB023, which means that both T cells and macrophages participated in the LPS-induced liver injury, and SKLB023 would prevented mice from attack by decreasing the activation of T cells and macrophages.
The cytokine secretion pattern of CD4 + T cells denes two main subsets of helper cells. Th1 cells produce IL-2, IFN-g, and TNF-a, whereas Th2 cells secrete IL-4, IL-10, and IL-13. The importance of CD4 + T cell dichotomy is underlined by the growing body of evidence that the outcome of numerous diseases critically depends on the Th1/Th2 balance in the accompanying immune responses. 11, 26 Our results showed that SKLB023 decreased the expression of IFN-g and increased the production of IL-4 at the same time, which indicated SKLB023 ameliorated LPS/D-GalN-induced acute liver injury by regulating the polarization of Th1/Th2 balance.
Macrophages play an important role in innate immunity and participate as effector cells in adaptive immune responses. They secrete multiple inammatory mediators (e.g., IL-1b, IL-6, and TNF-a) when induced in Th1-dominated immune responses and are therefore termed inammatory macrophages. 27 Our results showed that SKLB023 decreased the production of TNFa and IL-6 secreted by macrophages. It is reported that IL-6 produced by APCs can modulate the differentiation of CD4 + T cells into effectors Th1 or Th2 and it shied the Th1/Th2 balance toward the Th2 direction. 28 It seems that SKLB023 may suppress the expression of IL-6 and then modulated the differentiation of CD4 + T cells. However, we need some additional experiments to identify this hypothesis. In our previous study, pharmacokinetic proles of SKLB023 in mice were determined by Ultra Performance Liquid Chromatography (UPLC) assay, which suggested that the oral bioavailability of SKLB023 was 18.10%, with the half-time of 2.16 h. 21 Furthermore, the acute toxicity of SKLB023 on mouse was evaluated and the results showed that the LD 50 of SKLB023 was higher than 2 g kg À1 (p.o.) (unpublished data). The longterm toxicity of SKLB023 is conducting in our present project, and we here show a representative H&E staining result for histopathological evaluation of the liver, kidneys, heart, lungs, and spleen organs of mice treated with SKLB023 (50 mg kg À1 , p.o.) for one month (Fig. S4 †) . Both acute toxicity and H&E staining results indicated that SKLB023 is a potent antiinammatory compound with good safety and pharmacokinetic proles. In conclusion, our results indicated that SKLB023 protected mice from LPS/D-GalN-induced liver failure. These benecial effects of SKLB023 seem to be associated with the inhibition of pro-inammatory cytokines secreted by T cells and macrophages, which nally protects mice from liver injury. Therefore, SKLB023 offers a novel effective therapeutic strategy for the treatment of acute liver failure.
Materials and methods
Animal ethics and statement
BALB/c mice (6-8 weeks old; weight range 20-22 g) were obtained from Huafukang Biotechnology Company. Animals were maintained under constant conditions (temperature: 22 AE 2 C, humidity: 40-60%, 12 h light/12 h dark cycle). Standard lab chow and tap water were available ad libitum. All animal studies were carried out in accordance with the NIH guidelines for the care and use of laboratory animals (NIH Publication no. 85-23 Rev. 1985) and was approved by the Animal Care and Use Committee of Sichuan University in China (IACUC number: 20100318).
Reagents
SKLB023 was prepared as previously described. 21 Yield 92.8%; analytical HPLC purity ¼ 98.53%; white solid. N-Acetyl-Lcysteine (NAC), LPS, D-GalN and other analytical grade chemicals were purchased from Sigma. Antibodies were obtained from eBioscience. 18 Plasma enzyme activities of ALT, AST, ALP and ALB were measured by using an automated procedure, and the levels of serum TNF-a and IL-6 were analyzed by ELISA (R&D system, USA) according to manufacturer's instructions. In addition, parts of liver tissue in each mouse were quickly put into cold PBS for ow cytometry analysis, and other parts were xed in formalin for H&E analysis.
To calculate the survival rate, mice were challenged with 750 mg kg À1 D-GalN and 1.5 mg kg À1 LPS, which was reported as a lethal dose. 29 100 mg kg À1 NAC, 25 and 50 mg kg À1 SKLB023
were respectively pre-administrated 1 h before GalN/LPS challenge. The number of dead mice was counted every 2 h and the survival rates of mice were monitored for 24 h aer GalN/LPS injection.
T cells and macrophages analysis in the liver of mice injected with LPS/D-GalN
Liver samples were collected at 8 h and then perfused in situ with 10 ml cold PBS to remove circulating peripheral blood lymphocytes. Then, liver fragments were pressed through a sterile stainless steel screen in 50 ml cold PBS. The hepatocytes were collected at the bottom by low-speed centrifugation for analysis of macrophages, and the supernatant was collected for analysis of T cells. Macrophages and T cells were prepared as described previously 30, 31 with slight modications. Macrophages were further separated from hepatocytes by gradient centrifugation, and the method of selective adherence to plastic was used to purify the obtained cell population. The supernatant obtained from the low-speed centrifugation was collected and centrifuged, and the pellet was resuspended. The cell suspension was then layered on top of a density cushion of 40%/ 70% discontinuous Percoll (Pharmacia Biotech, Uppsala, Sweden) and centrifuged to obtain the lymphocyte fraction at the interface. Cells were collected, lysed with RBC lysing buffer and washed with cold PBS. T cells and macrophages were stained with anti-mouse CD3, CD11b, CD68 and F4/80 antibodies (eBioscience, San Diego, CA) and subjected to FACS analysis.
Histological analysis
Livers were removed (n ¼ 8 per group) from animals under pentobarbital anesthesia (100 mg kg À1 ; intraperitoneal injection). Livers were sectioned, xed in 10% formalin, and embedded in paraffin. The sections were then stained with hematoxylin and eosin. Extent of liver injury was evaluated according to Heijnen's technique. 32, 33 Briey, liver injury was assessed as the sum of individual scores ranging from 0 to 3 (0, no injury; 1, mild; 2, moderate; 3, severe) for the following parameters: cytoplasmic color fading, vacuolization, nuclear condensation, nuclear fragmentation, nuclear fading, and erythrocyte stasis.
T cells isolation and pro-inammatory cytokines analysis
Splenocytes were collected from BALB/c mice, treated with RBC lysis buffer (Sigma, St. Louis, MO), and T cells were incubated in 6-well Costar plates in the presence of Con A (5 mg ml À1 ) and SKLB023 at the concentration of 5, 10, 20 mM for 72 h. Cytokine contents (IL-4 and IFN-g) were measured in 72 hour supernatants of the spleen cell cultures using a specic enzyme-linked immunosorbent assay (ELISA) for mice (MiniKit; Endogen), according to manufacturer's instructions. Cells were then stained for the surface expression of CD3, CD4, and CD8 (Biolegend, CA, USA). Samples were then washed and examined by ow cytometry with CellQuest soware (BD FACS Calibur).
Preparation of liver macrophages (Kupffer cells) and cytokines analysis
BALB/c mice were anaesthetized by diethyl ether inhalation and liver samples were collected aer perfusion. The liver tissues were dispersed by 0.1% type IV collagenase digestion and ltered through a 74 mm stainless steel wire mesh to remove undigested tissue. Macrophages was prepared as described in Materials and methods (4.4) . Macrophages were cultured with DMEM medium alone or activated with 2 ng ml À1 IFN-g and 100 ng ml À1 LPS, and treated in absence or presence of SKLB023 (5, supernatant were determined by ELISA (R&D system, USA) according to manufacturer's instructions.
Statistical analysis
Data were expressed as mean AE SD and differences between group means were calculated by Student's t test or by ANOVA where appropriate. P values less than or equal to 0.05 were considered signicant. 
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